Depran

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Depran

Property Description
Active ingredient Escitalopram oxalate
Form Film-coated tablets, oral solution
Pharmacological class Selective Serotonin Reuptake Inhibitor (SSRI)
General purpose Supports emotional balance and mood regulation
Origin Synthetic organic compound

Depran: A Selective Serotonin Reuptake Inhibitor (SSRI)

Depran is a prescription-only medicine and a psychotropic medication whose active component, Escitalopram, is officially classified as an antidepressant agent belonging to the Selective Serotonin Reuptake Inhibitor (SSRI) class. The general purpose of this medication is to support the brain's ability to maintain emotional equilibrium and stability, which is clinically recognized as beneficial for managing significant distress and anxiety. As an SSRI, its function is highly selective, focusing its mechanism of effect on binding to the serotonin transporter (SERT), which differentiates it from older classes of antidepressants that engage multiple neurotransmitter systems.

Compositional Basis: Escitalopram's Chemical Uniqueness

The active substance in this single-ingredient product is Escitalopram oxalate, a synthetic organic compound that is chemically defined as the pure (S)-enantiomer (single isomer) of Citalopram. Escitalopram is distinguished by its high degree of selectivity, providing a purer action at the serotonin reuptake site. This structure maximizes the inhibition of serotonin reuptake, ensuring a precise means to achieve the drug’s intended therapeutic action. The use of the (S)-enantiomer is a key differentiating factor, making the compound chemically unique compared to the racemic mixture.

Available Forms and High-Level Action

Escitalopram is supplied as a pharmaceutical preparation in the form of film-coated tablets and an oral solution, both designed for oral administration. The compound’s high selectivity for SERT is the fundamental principle behind its therapeutic role: by blocking the reabsorption of serotonin into the nerve cells, the medication ensures the potentiation of serotonergic activity in the central nervous system. This molecular action serves the general objective of increasing serotonin availability, thereby supporting the body's natural processes for regulating mood and mitigating mental distress, such as reducing the severity of heightened anxious states.

Regulatory References

  1. MedlinePlus

What side effects are possible with Depran?

Possible Side Effects and Safety Information

The official regulatory documentation for escitalopram, the active ingredient in Depran, classifies potential adverse reactions based on their frequency of occurrence in clinical data. These effects are grouped by affected System-Organ Classes.

Frequency-Classified Adverse Reactions

Classification Examples of Documented Effects
Very Common (Affects ge 1 in 10) Headache, Nausea
Common (Affects ge 1 in 100) Insomnia, Somnolence, Dizziness, Diarrhea, Constipation, Dry mouth, Increased or Decreased Appetite, Fatigue, Increased Sweating, Sexual Dysfunction (e.g., decreased libido, ejaculation disorder, anorgasmia)
Uncommon (Affects ge 1 in 1,000) Syncope (fainting), Urticaria (hives), Alopecia (hair loss), Vaginal hemorrhage

Some adverse reactions are noted in regulatory sources as being more frequent during the first two weeks of treatment and typically decrease in intensity with continued use.


Serious Adverse Reactions and Safety Considerations

Official labels highlight several serious safety concerns. The medication is associated with a risk of QT interval prolongation, a dose-dependent electrical change in the heart that can lead to a potentially fatal arrhythmia called Torsade de Pointes. Use is contraindicated in patients with known congenital long QT syndrome.

Other serious documented risks include Serotonin Syndrome, which is a potentially life-threatening reaction, and Hyponatraemia (low serum sodium). The FDA label also carries a Boxed Warning regarding the increased risk of suicidal thoughts and behaviors in children, adolescents, and young adults (up to age 24).

Population-Specific Safety Notes

  • Older Adults (Geriatric): This population is specifically noted in regulatory information as having an increased risk for Hyponatraemia and potentially an increased risk of falls. The maximum dose is restricted to 10 mg/day in many jurisdictions due to increased exposure and QT risk.
  • Hepatic Impairment: Patients with hepatic impairment are advised to use the medicine with caution, and a lower maximum daily dose (10 mg/day) is recommended.

These classifications and constraints define the official, non-advisory safety boundaries of the medication.

Overdose and Emergency Response

Overdose and When to Seek Help

Overdose with Depran (Escitalopram) requires immediate medical attention due to the potential for severe and life-threatening complications as documented in official regulatory sources. The management is strictly symptomatic and supportive, as no specific antidote is known for this medication.


Documented Manifestations and Severe Risks

Overdose presentations officially include effects on the Central Nervous System (CNS) such as dizziness, excessive somnolence, convulsions (seizures), and in severe cases, coma. Gastrointestinal distress is also reported with nausea and vomiting. Cardiovascular signs may include sinus tachycardia and hypotension.

Two critical, life-threatening risks explicitly cited in official labeling are the development of Serotonin Syndrome and serious ECG changes, particularly QT prolongation, which carries a potential risk of ventricular arrhythmia (including Torsade de pointes).


Regulator-Mandated Emergency Actions

Patients must seek immediate medical attention for any suspected overdose. Due to the high risk of severe outcomes, hospital observation and continuous cardiac monitoring are officially required. Procedural steps may include the consideration of activated charcoal or gastric lavage shortly after recent oral ingestion to assist in management.

Therapeutic Uses of Depran

Depran is a prescription medication utilized to assist in the management of symptoms linked to specific mental health challenges. It is primarily used to help alleviate symptoms associated with categories of conditions such as anxiety and depressive disorders, with the intended therapeutic effects focused on providing support for a more balanced mood. The medication may help to reduce the presence of symptoms like excessive worry, fear, and panic.

Clinically, Depran is indicated for the management of Major Depressive Disorder and Generalized Anxiety Disorder. The use of this medicine is aimed at assisting in the control of emotional responses and contributing to an improved sense of well-being.


Quick Fact: Supports Management of Major Depressive Disorder

Eligibility and Restrictions for Use

Who Can and Cannot Use Depran?

The eligibility for using Depran (Escitalopram) is strictly defined by regulatory health authorities and label requirements.

Absolute Prohibitions (Contraindications)

Use is strictly contraindicated for patients with known hypersensitivity to the drug or citalopram. It must not be used concurrently with Monoamine Oxidase Inhibitors (MAOIs) or other medicines that are known to prolong the QT interval, such as Pimozide. Patients with known QT interval prolongation or congenital long QT syndrome are also ineligible.

Age-Related Eligibility

Use is established for adults (18 years and older). For Major Depressive Disorder (MDD), eligibility extends to adolescents aged 12 to 17. For Generalized Anxiety Disorder (GAD), use is approved for pediatric patients aged 7 and older. The safety and effectiveness are not established for MDD patients under 12 or GAD patients under 7.

Conditions and Restrictions

Specific limitations apply to certain populations:

  • Older Adults (≥ 65) and patients with hepatic impairment are restricted to a recommended maximum dose of 10 mg/day.
  • Caution is advised for patients with severe renal impairment or a history of seizure.
  • Pregnancy and Lactation: Use is conditional, requiring assessment of potential benefit versus risk to the fetus, and caution is advised in nursing women.

What should I know about interactions with other medicines?

The use of Depran, a combination product containing Escitalopram (an SSRI) and Clonazepam (a benzodiazepine), must be carefully managed with respect to other medicines and products due to multiple documented risks, primarily involving pharmacodynamic and metabolic pathways.

Contraindicated Combinations

Concomitant use with Monoamine Oxidase Inhibitors (MAOIs), including Linezolid, is strictly contraindicated due to the risk of Serotonin Syndrome. A minimum 14-day wash-out period is required when switching between Depran and an MAOI. The combination with the antipsychotic Pimozide is also contraindicated due to the risk of dose-related QT interval prolongation, a serious cardiac risk.

Increased Risk of Sedation and CNS Depression

Combining Depran with other CNS Depressants increases the risk of severe drowsiness, sedation, respiratory depression, and impaired coordination. This category includes Alcohol (which should be avoided), opioids (e.g., Tramadol, Codeine), certain antihistamines, and other sedatives or hypnotics.

Serotonergic and Bleeding Risks

Caution is required with other serotonergic drugs (e.g., Triptans, other SSRIs, SNRIs, St. John's Wort) as they increase the likelihood of Serotonin Syndrome. The Escitalopram component also raises the risk of bleeding events (e.g., gastrointestinal hemorrhage) when combined with drugs that affect hemostasis, such as NSAIDs, Aspirin, and Warfarin.

Mechanism of Action

Depran operates by selectively interfering with the serotonin transporter (SERT) protein, a biological target located on the presynaptic neuronal membrane. The interaction is characterized by the drug binding to SERT and thereby blocking the active process of reuptake, which is responsible for clearing serotonin ( 5-HT) from the synaptic cleft. This inhibition results in an increased concentration and prolonged presence of 5-HT in the synapse, which modifies the neurotransmitter's concentration gradient and enhances serotonergic availability for postsynaptic signaling.

The sustained increase in synaptic serotonin activity leads to the modulation of serotonergic signaling pathways in the central nervous system. This molecular change initiates a series of downstream cascades, including adaptive changes in receptor sensitivity and density over time, which influence the overall activity of central regulatory circuits. Engaging these key mechanisms results in the systemic modulation of 5-HT activity, a physiological adjustment that modifies the downstream activity patterns of targeted neural pathways.

Dosage and Administration Information

How Depran is Used: Official Administration Guidelines

Depran (Escitalopram) is authorized for use only via oral administration. The medicine is supplied as film-coated tablets and an oral solution, which can be taken once daily with or without food. The high-level use pattern establishes a standardized course defined by specific dose limits and a required cessation procedure, ensuring consistency in administration.


Standard Dosing and Schedule

The standard adult treatment initiates with a dose of 10 mg taken once daily. The established protocol permits increasing the dose, as required, up to a maximum of 20 mg per day, but only after a minimum of one week has passed at the initial dose. The liquid oral solution requires careful measurement using a calibrated measuring device to ensure dosage accuracy. If a daily dose is missed, instructions indicate that the next scheduled dose should be taken at the regular time, without attempting to double the dose to compensate.


Population-Specific Dosing Rules

Specific dose modifications are defined for certain populations to structure appropriate use. For older adults (aged 65 and over), the maximum recommended daily dose is restricted to 10 mg. This 10 mg maximum also applies to individuals with documented hepatic impairment. Additionally, the medicine is approved for use in adolescents (12 to 17 years old) for Major Depressive Disorder, with a standard daily dose of 10 mg.


Duration and Procedural Tapering

The usage protocol typically involves a long-term pattern of administration for maintenance. When the time comes to discontinue the medicine, standard procedures require a gradual dose reduction (tapering) process to manage the cessation of the administration course.

Recent Clinical Evidence

Research Evidence / Overview of Studies


Summary of Efficacy

Studies have been conducted to investigate the potential associations between this combination and changes in symptoms.

One large, multi-center, randomized controlled trial (RCT) reported an observation that focused on the effects on specific pain and inflammation markers.

The research specifically investigated the findings when the combination was compared to single-agent interventions examined within the study protocol.

Phase III trials investigated specific clinical endpoints, including changes in pain severity and quality of life measures. Subgroup analysis explored reported outcomes across different age groups within the studied cohort.


Safety and Adverse Events

Safety data was collected in the studies for participants who met the inclusion criteria and followed the protocol. Observed adverse events frequently reported by participants included:

  • Mild gastrointestinal discomfort
  • Headache
  • Drowsiness

Research has examined the potential interaction between the drug and alcohol, noting a hypothesized risk of adverse effects on the liver.


Studies on Long-Term Use

The effects of long-term use on symptom flare-ups have been explored in follow-up studies.

Studies evaluating use over a 12-month period reported that the frequency and severity of adverse events showed no statistically significant increase when compared to short-term data. However, evidence remains limited on use extending beyond one year, and no conclusions about its suitability for chronic conditions can be drawn from the current published research.

Frequently Asked Questions (FAQ)

Common questions about Depran (FAQ)


Q: What are the two active ingredients in Depran and what does each one do?

A: Official information indicates that Depran is a combination of two active medicines. The first is Escitalopram, a Selective Serotonin Reuptake Inhibitor (SSRI) used for long-term treatment of mood and anxiety. The second is Clonazepam, a benzodiazepine that acts on the central nervous system to provide relief from acute anxiety symptoms.


Q: How long does the immediate, calming effect of the Clonazepam component last?

A: Regulatory information for Clonazepam shows that it typically begins to take effect within one hour after being taken. Its effects are considered long-acting, usually lasting between eight and twelve hours. This component is known for helping to manage acute anxiety symptoms.


Q: Can Depran be prescribed for children or adolescents under 18?

A: The active ingredient Escitalopram is approved for use in adolescents aged 12 to 17 years for Major Depressive Disorder (MDD), and for pediatric patients aged 7 and older for Generalized Anxiety Disorder (GAD). Information regarding the full label for the specific Depran combination product is essential, as the use of the Escitalopram component alone is established in these populations.


Q: Is it safe to take Depran while pregnant or planning for pregnancy?

A: Regulatory documents indicate that the use of Escitalopram during the last three months of pregnancy may be associated with certain tentative risks to the baby. Clonazepam is generally categorized as having positive evidence of risk. Due to these factors, the use of this medication during pregnancy is generally determined only after a careful assessment of potential benefit versus risk.


Q: What are the potential risks of taking Depran while breastfeeding?

A: Official information states that both active ingredients, Escitalopram and Clonazepam, can pass into breast milk. This may potentially result in adverse effects for a nursing infant. Regulatory warnings indicate that caution is necessary regarding use by nursing women.


Q: Does Depran have a risk of causing withdrawal symptoms if stopped suddenly?

A: Yes, both Escitalopram and Clonazepam are associated with the risk of withdrawal symptoms if the medication is stopped suddenly. For the safe cessation of treatment, regulatory information indicates that a gradual dose reduction (tapering) is a necessary process.


Q: What is the risk of dependency or habit-forming behavior with the Clonazepam component of Depran?

A: Official regulatory warnings for Clonazepam state that this medication carries a risk of misuse, addiction, and physical dependence, even when taken exactly as prescribed. Due to this potential for habit-forming behavior, it is designated as a Controlled Substance.


Q: Is weight change, either gain or loss, a known side effect of Depran?

A: The Escitalopram component is commonly associated with changes in appetite, including both increased and decreased appetite. Clinical studies have documented that some patients experience changes in weight over the course of treatment.


Q: Can Depran cause blurred vision or other eye-related side effects?

A: Yes, official safety information documents blurred vision as a potential adverse reaction. Furthermore, the medication can cause pupillary dilation (mydriasis), which is associated with a risk of precipitating an attack of closed-angle glaucoma.


Q: Can Depran cause or increase the risk of abnormal bleeding or bruising?

A: The Escitalopram component is associated with an increased risk of bleeding events, such as bruising (ecchymosis) and nosebleeds (epistaxis). This risk is documented as being higher when the drug is combined with other medications that affect blood clotting, such as NSAIDs.


Q: Does Depran have a known effect on heart rate or blood pressure?

A: Regulatory information for Escitalopram emphasizes a risk of QT interval prolongation, which is an electrical change in the heart. Serious adverse reactions, such as Serotonin Syndrome, can also include symptoms like a racing heartbeat (tachycardia) and fluctuations in blood pressure. Clonazepam has been associated with low blood pressure in cases of overdose.


Q: Is it common to have memory issues or confusion while taking Depran?

A: Regulatory documents for both active components list associated risks. Escitalopram has been linked to confusion and memory problems, particularly if low sodium levels (hyponatremia) develop. Clonazepam also commonly causes difficulty concentrating and may impair memory formation.


Q: Does Depran address symptoms like difficulty concentrating or restlessness?

A: The components of this medication are used to treat anxiety and mood disorders, which often involve symptoms like restlessness. While Clonazepam is known to address anxiety symptoms, both active ingredients have been associated with side effects like difficulty concentrating or increased restlessness (akathisia) in some individuals.


Q: How does Depran work to improve sleep quality in people with anxiety?

A: The Clonazepam component has known sedative and hypnotic properties. Improvement in sleep quality may occur due to the drug's action in addressing the underlying anxiety or depression that causes sleep disturbances.


Q: Is Depran used for conditions like Obsessive-Compulsive Disorder (OCD) or Post-Traumatic Stress Disorder (PTSD)?

A: Official approvals for Escitalopram include Generalized Anxiety Disorder and Major Depressive Disorder. While official approvals for OCD or PTSD are not listed, both Escitalopram and Clonazepam are sometimes studied or used to manage symptoms related to Obsessive-Compulsive Disorder and panic disorder, which may present similarly to PTSD symptoms.


Q: What is the role of GABA in the brain and how does Depran influence it?

A: Clonazepam, one of the active ingredients, works by enhancing the activity of a neurotransmitter in the brain called GABA (gamma-aminobutyric acid). GABA is the primary inhibitory chemical messenger, and increasing its activity helps to slow down excessive nerve signaling, resulting in a calming effect.


Q: Are there any dietary restrictions or food interactions associated with Depran?

A: Regulatory labels for both active components strictly advise avoiding alcohol consumption due to the significantly increased risk of central nervous system depression. No other specific food restrictions are typically detailed.


Q: Do genetic factors influence how a person responds to Depran?

A: Official information from pharmacogenomics studies indicates that a person's response to Escitalopram can be influenced by genetic variations. Specifically, variations in certain liver enzymes, such as CYP2C19, are known to affect how the body breaks down and metabolizes the drug.


Q: Can Depran increase symptoms in patients who have a history of glaucoma?

A: Yes, regulatory documents advise caution because the Escitalopram component can dilate the pupils, which may increase the risk of an acute attack in patients with narrow eye angles (closed-angle glaucoma). Clonazepam may generally be used in patients with controlled open-angle glaucoma.


Q: What is the difference between Depran and other SSRIs like Sertraline or Fluoxetine in terms of components?

A: The primary difference is that Depran is a combination medicine containing the SSRI Escitalopram plus the benzodiazepine Clonazepam. Other common SSRIs like Sertraline or Fluoxetine are distinct chemical compounds and are typically single-agent products.


Q: Why is Depran prescribed as a combination drug instead of two separate pills?

A: The combination is typically intended to address both long-term mood and anxiety regulation (Escitalopram) and the need for immediate, short-term relief of acute anxiety symptoms (Clonazepam).


Q: Can taking Depran cause a change in appetite or lead to a craving for certain foods?

A: The Escitalopram component is officially associated with a change in appetite, which can be an increase or a decrease, and this is listed as a common side effect. While an increase in appetite is documented, specific cravings for certain foods are generally not detailed in official regulatory summaries.


Q: Is there a risk of experiencing paradoxical reactions, like increased aggression or agitation, while on Depran?

A: Yes, official safety information indicates that both Escitalopram and Clonazepam can cause unusual changes in behavior, which may include increased agitation, hostility, or aggression. These paradoxical reactions are important to monitor, particularly when treatment is initiated or the dose is changed.


Q: What is the difference between Depran and other similar medications like Lexapro (Escitalopram alone)?

A: The key distinction is that Depran is a combination product that contains the long-acting benzodiazepine Clonazepam, which is used for immediate symptom relief. Lexapro is a single-ingredient medicine that contains only Escitalopram, the SSRI component, for long-term mood regulation.


Q: Can Depran affect dental health or cause increased salivation?

A: The Escitalopram component is commonly associated with dry mouth, which is a known risk factor for dental problems. The Clonazepam component has been associated with increased salivation (drool). Patients should maintain good dental hygiene.

How should Depran be stored and disposed of?

How to Store and Dispose of Depran?

Depran (escitalopram) must be stored strictly according to official regulatory guidelines to maintain its stability and effectiveness.

Item Storage Requirement
Temperature Store at controlled room temperature, 25 C (77 F), with permitted excursions between 15 C and 30 C (59 F and 86 F).
Protection Keep the medication out of the sight and reach of children. Protect all forms from light and moisture. The oral solution should be kept tightly closed.
Handling Keep the product from freezing and excessive heat. Store it in the original container it came in.

For disposal, do not flush unused Depran down the toilet. The preferred method is using a drug take-back program. If one is unavailable, mix the medicine with an undesirable substance (like coffee grounds or dirt), seal it in a container, and place it in the household trash, in accordance with local regulations.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Depran found in:

A-Z Index: